Please login to the form below

LAMA

This page shows the latest LAMA news and features for those working in and with pharma, biotech and healthcare.

AZ prepares to file COPD triple, taking on rival GSK

The KRONOS trial of PT010 – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – was presented at a medical congress ... triple –

Latest news

AZ rival to GSK’s COPD drug Anoro fails head-to-head test

The results of the AERISTO trial are a blow to AZ’s ambitions for Bevespi (glycopyrronium/formoterol fumarate) – a long-acting muscarinic agonist (LAMA)/long-acting beta agonist (LABA) combination that ... The real battleground between the two
AZ’s COPD triple data sets up market clash with GSK

AZ has reported phase III data from the KRONOS trial of its PT010 triple - combining long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid ... on LABA vilanterol, LAMA
EMA approves GSK’s triple COPD therapy

The same indication was approved by the FDA in September, and makes Trelegy the first drug on the market to combine an ICS, LABA and long-acting muscarinic receptor antagonist (LAMA)
With US approval, GSK now needs rapid uptake for COPD triple

The three-drug product delivers a long-acting beta agonist (LABA), a long-acting muscarinic antagonist (LAMA) and an inhaled corticosteroid (ICS) from a single device, and is the first product
GSK closes in on EU approval for triple COPD therapy

The new product adds long-acting muscarinic receptor antagonist (LAMA) umeclidinium to the ICS/LABA combination, which has proved so successful in GSK's big-selling Advair/Seretide (fluticasone propionate/salmeterol) ... GSK thinks it has a decent head

More from news
Approximately 3 fully matching, plus 50 partially matching documents found.

Latest Intelligence

Medius Deal Watch table for February 2015

Collaboration - discover, develop, commercialise. 339. Theravance/ Mylan. TD-4208- a novel once-daily nebulised long-acting muscarinic antagonist (LAMA) - COPD.
Pharma deals in February 2015

The co-development and marketing deal with Theravance involves TD-4208 a novel, phase 3 ready, once-daily, nebulised, long-acting muscarinic antagonist (LAMA) under development to treat COPD and other
Deal Watch table for June 2013

2, 150. Pearl Therapeutics / AstraZeneca. Acquisition. Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III).
Pharma deals during June 2013

Currently in phase III clinical development for COPD, this combination of a long acting beta-2 agonist (LABA) and a long acting muscarinic antagonist (LAMA) is expected to become an important

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Senior Writer, Healthcare Advertising, London: Excellent package

Account Director, Healthcare Advertising Agency: Salary TBC

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Account Manager- 4 days per week or full-time: Salary TBC

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Healthcare PR Senior Account Manager: Salary TBC

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Market Access Consultant - Greater Manchester: Negotiable

Systematic Review Lead- London: Negotiable

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Associate Scientific Director: Salary TBC

Sudler London - Senior Medical Writer: Competitive

Senior Account Manager – Healthcare Advertising: Salary TBC

Account Manager: Negotiable

Senior Training Manager - Surrey: Competitive Salary &Bonus

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Senior Medical Writer: Salary is DOE

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Graduate Scientific Editor: DOE

Medical Writer - Creative and Scientific Projects: DOE

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....